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Topical methylglyoxal bis(guanylhydrazone) (MGBG) 
and alpha-difluoromethylornithine (DFMO) individ-
ually have been shown to produce partial clinical im-
provement in psoriasis. In an effort to further enhance 
therapeutic activity, studies were designed to optimize 
percutaneous penetraton of DFMO in vitro and to deter-
mine the effects of the combination of DFMO and MGBG 
on DNA synthesis and polyamine levels in hairless 
mouse skin. 
MGBG was shown to be more effective than DFMO in 
inhibiting DNA synthesis in vitro and in vivo. Maximum 
in vitro percutaneous penetration of DFMO (5%) was 
obtained in Vehicle N containing 10% Azone (297 !J.g/h/ 
cm2 ) . Topical administration of the combination of 5% 
DFMO and 0.1 o/o MGBG in this vehicle produced a 
greater inhibition of DNA synthesis and depletion of 
polyamine levels than either drug individually. The si-
multaneous topical administration ofDFMO and MGBG, 
allowing the use of lower concentrations of the more 
toxic MGBG, may be useful for therapy of psoriasis and 
other cutaneous disorders associated with abnormalities 
in polyamine metabolism. 
Hyperproliferative cutaneous disorders such as psoriasis and 
many premalignant and malignant lesions are characterized by 
increased levels of polyamines and their associated biosynthetic 
enzymes [1-3). The normalization of polyamines by effective 
therapeutic moda lit ies [1,4,5] has provided the rationale for the 
use of polyamine inhibitors in the therapy of these diseases. 
Local (topical or intra lesional) metbylglyoxal bis(guanyl-
hydrazone) (MGBG), a competitive inhibitor of S-adenosyl-
methionine decarboxylase (SAMDC) (Fig 1) produces benefi-
cial therapeutic effects in psoriasis [6) and cutaneous malig-
nancies (7), although in psoriasis topical delivery of 10% 
MGBG produces an unacceptable level of irritation. 
The topical delivery of alpha-difluoromethylornithine 
(DFMO) (10% in a cream base), an irreversible inhibitor of 
ornithine decarboxylase (Fig 1) , has marginal therapeutic ac-
tivity in psoriasis [8] . The therapeutic delivery in more effective 
vehicles has not been explored. 
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Abbreviations: 
DFMO: alpha-dilluoromethylornithine 
MGBG: methylglyoxal bis(guanylhydrazone) 
ODC: orni thine decarboxylase 
SA MDC: S-adenosylmethionine decarboxylase 
TPA: 12-0-tetradecanoyl-phorbol-13-acetate 
DFMO in combination with MGBG has been shown to have 
a therapeutic synergism in both experimental tumor models as 
well as in human malignancies [9,10]. Effective topical delivery 
of this combination may be therapeutically useful in prolifera-
tive disorders of the skin. 
The objectives of this study were (1) to quantitate the dose 
dependence of the combination of DFMO and MGBG on in-
hibition of DNA synthesis in 12-0-tetradecanoyl-phorbol-13-
acetate (TP A)-treated hyperproliferative mouse epidermis in 
vitro; and (2) to optimize the vehicle for topical delivery of 
DFMO in vitro and study the effects of topical DFMO and 
MGBG on DNA synthesis and cutaneous polyamine levels in 
mouse epidermis in vivo . 
MATERIALS AND METHODS 
MGBG was obtained from Aldrich Chemical Co., Milwaukee, Wis-
consin; Vehicle N (alcohol 47.5%, water, laureth-4, isopropyl alcohol 
4%, propylene glycol) from Neutrogena Corp., Los Angeles, California; 
Azone (1 -dodecylazacycloheptan-2-one) and N-methylpyrrolidone 
from Nelson Research, Irvine, California. [Methyl-3H]thymidine (sp 
act 25.0 Ci/mmol) was purchased from Amersham, Arlington Heights, 
Illinois. TP A was purchased from Consolidated Midland Corporation. 
DFMO and [14C] -DFMO (sp act 60 mCi/mmol) were obtained from 
Merrell Dow Pharmaceuticals, Cincinnati, Ohio. Albino hairless mice 
(Skh:HR/ 1), aged 2-3 months, were purchased from Temple Univer· 
sity. 
In Vitro Percutaneous Penetration Studies 
The percutaneous penetration of DFMO was measured in glass 
di ffusion cells at 28"C as previously described [11] . ["C] -DFMO (0.25 
llCi/0.1 ml) at various concentrations was applied in selected vehicles 
to the epidermal surface of excised domestic pig skin (0.5 ml/cm2). 
DFMO penetration was quantitated by liquid scintillation counting. 
Thr_ee diffusion cells were run for each test condition (concentration, 
veh1cle) . 
In Vitro Incubation Studies 
The dorsal skin of hairless mice was treated in each of 6 sites/mouse 
with 17 nmol of TPA in 0.15 ml acetone. After 6 h, a period sufficient 
for polyamine biosynthetic enzymes to peak [12], the animals were 
sacrificed and 'T'PA-treated skin excised. Three minced 4-mm skin 
biopsies were placed in tubes containing BME culture medium with 
Hanks' salts, penicillin (100 U/ml), streptomycin (100 11g/ml), and 
gentamycin (50 llg/ ml) . The medium contained various concentrations 
of either MGBG or DFMO alone, or a combination of both drugs. 
Tubes were incubated for 18 h at 37"C under 95% air-5% C02 to 
achieve maximum DNA synthesis activity. Tritiated thymidine (4 11Ci/ 
ml) was then added to the medium and incubation continued for 1 h. 
Tissue specimens were then rinsed twice in cold 0.9% saline, and 
digested in 0.2 ml 0.5 N NaOH at 90"C for 90 min. DNA was extracted 
and assayed us ing the technique described by Halprin eta! [1 3]. DNA 
synthesis was calculated as cpm per 11g DNA and the data expressed as 
percent of control DNA synthesis. 
In Vivo Studies 
Effects on DNA Synthesis: Drug or vehicle alone (control) (50 Ill) 
was applied to the backs of normal hairless mice (6 mice/group) daily 
for 7 days. Six hours after the last application mice were injected with 
tritiated thymidine (2 11Ci/g body weight). One hour after administra· 
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FIG 1. Polyamine biosynthetic pathway. 
t ion of isotope, a nimals were sacrificed by cervical dislocation and 
t reated dorsal skin excised. Epidermis was removed after incubating 
t h e s kin specimens for 1 h at 37•c in 2 M sodium bromide and DNA 
extr acted as above [13]. Results of epidermal DNA synt hes is were 
calculated as cpm/ pg DNA and exp ressed as percent of cont rol. 
Effects on cutaneous polyamine levels: Drug or vehic le (cont rol) was 
applied as above to the backs of hairless mice (3 mice/group) da ily for 
7 d ays. Animals were sacrificed 4 h afte r t he last application a nd the 
dorsal skin removed for polyamine ana lysis. Epidermal polyamine 
levels were quant itated by an amino acid analyzer us ing the technique 
previously desc ribed [14]. 
RESULTS 
In Vitro Percutaneous Penetration 
The penetration of 1% DFMO was measured in 4 vehicles: ( 1) N -methylpyrrolidone: isopropanol:water ( 43:30:27) (2 p.g/h/ 
cm2 ); (2) isopropanol:water:Azone (50:48:2) (6 p.g/h/cm2); (3) 
Vehicle N (27 p.g/h/cm2 ) ; (4) Vehicle N:Azone (9:1) (36 p.g/h/ 
em 2 ). Vehicle N provided t he most effective delivery while the 
addition of Azone (10%), a penetration-enhancing agent [15], 
increased DFMO penetration 1.3-fold . Comparing the effect of 
DFMO concentration (0.5%, 1%, 5%, 10%) in Vehicle N- 10% 
Azone, maximum penetration (297 p.g/h/cm2 ) was achieved 
with 5% DFMO (Fig 2). Increasing DFMO concent ration to 
10% did not further enhance DFMO penetration. 
Effects of DFMO and MGBG on DNA Synthesis In Vitro 
A hyperproliferative model was used to quantitate t he con-
centration-dependent effects of DFMO and MGBG, a lone and 
in combination, on DNA synthesis in vitro. In t his model 
topical application of TPA to hairless mouse skin stimulates 
the polyamine biosynthetic enzymes, ornithine decarboxylase 
(ODC) and S-adenosylmethionine decarboxylase (SAMDC) 
[12], leading to increased levels of intracellular polyamines and 
epidermal DNA synthesis [16,17). In this model a submaximally 
inhibiting dose of MGBG (5 X 10- 5 M) producing 50% inhibi-
t ion, used together with increasing DFMO concentrations, gave 
increasing inhibit ion of DNA synthesis (90% inhibition with 5 
X 10-:J M DFMO) vs 68% inhibi tion with 5 X w -:! M DFMO 
alone (Fig 3). Thus the more toxic MGBG can be used at lower 
doses and achieve enhanced inhibition of DNA synthesis when 
combined with DFMO. 
Effects of Topical DFMO and MGBG In Vivo 
DNA Synthesis: Topical 0.1% MGBG alone produced 36% 
inhibition of DNA synt hesis, while greater than 90% inhibition 
was obtained with higher concent rations (1 %, 5%, 10%) (Fig 
4). DFMO alone (0.1- 5%) resulted in approximately 50% in-
hibition. When these drugs were applied simultaneously (5% 
DFMO and 0.1% MGBG) 83 % inhibition was obtained, thus 
exceeding the effect of t hese drug concentrations when applied 
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FIG 2. Effect of DFMO concentration in Azone:Vehicle N (1:9) on 
percutaneous penetration in vit ro (mean ± SD) . 
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FIG 3. Effects of DFMO and MGBG combinations on mouse epi-
dermal DNA synt hesis in vi t ro (mean ± SD). 
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FIG 4. Effect of topical DFMO a nd MGBG combinations on epi-
derma l DNA synthesis in hairless mice. 
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FIG 5. Effect of topical DFMO and MGBG combinations on epi-
dermal polyamine levels in hairless mice. (1) 0.1% MGBG; (2) 5.0% 
DFMO; (3 ) 5.0% DFMO + 1.0% MGBG; (4) 5.0% DFMO + 0.1% 
MGBG. 
individually (DFMO p < 0.01; MGBG p = 0.12). The topical 
application of 1- 5% MGBG daily for 7 days produced severe 
skin erosion in the mice, whereas only mild irritation was 
obtained with 5% DFMO alone or in the presence of 0.1% 
MGBG. 
Polyamine synthesis: Both 0.1% MGBG and 5% DFMO, 
individually, decreased putrescine levels, without significantly 
altering spermine or spermidine (Fig 5). The combination of 
DFMO with 0.1 % MGBG significantly depressed putrescine (p 
< 0.05), spermidine (p < 0.05), and spermine (p < 0.1) levels, 
with comparable effects obtained with combinations using 1% 
MGBG. 
DISCUSSION 
The present studies show that the combined use of DFMO 
and MGBG produce an inhibition of epidermal DNA synthesis 
in vitro and in vivo to an extent that is not achieved by either 
of the drugs individually. With this topical drug combination, 
these inhibitory effects are achieved with minimal cutaneous 
irritation, whereas higher concentrations of MGBG alone pro-
duce extreme cytotoxicity leading to skin erosion, both in this 
animal model [18] and in psoriasis [6]. These results are in 
agreement with those recently published by Kapyaho et al 
(19,20] which demonstrated that topical 20% DFMO and 50 
mM MGBG in a lipophilic ointment prevents the UVB-induced 
epidermal polyamine accumulation and increased DNA synthe-
sis in mouse skin . The much higher concentrations of DFMO 
and MGBG used in that study resulted in very high (millimolar 
range) intracellular levels of MGBG which affected macromo-
lecular synthesis in both the proliferative and differentiated 
epidermal cell compartments. The present studies indicate that 
50% inhibition of epidermal DNA synthesis is achieved in vitro 
with 5 X 10-r. M MGBG. This would indicate that much lower 
levels of MGBG would be needed to achieve cellular alterations 
in polyamines and inhibition of cell proliferation. Our previous 
studies have shown that the percutaneous penetration of 
MGBG in Vehicle N in vitro is 3 iJ.g/h/cm2 [18], which approx-
imates the level of drug required for inhibition of DNA synthe-
sis in vitro. Similarly, the level of percutaneous penetration of 
Vol. 85, No.6 
DFMO (297 iJ.g/h/cm2) approximates the concentration (lo- 3 
M) required to produce 50% inhibition of epidermal DNA 
synthesis in vitro. 
Previous studies have demonstrated that the "priming" con-
cept involving pretreatment with DFMO followed by MGBG is 
effective in enhancing the cellular uptake of MGBG and anti-
proliferative effects in mouse skin [19,20]. In the present study 
the simultaneous administration of both drugs provides a sim-
pler approach to therapy. 
Recent studies have shown that the combination of DFMO 
and MGBG produces a selective inhibition of growth of pso-
riatic vs normal keratinocytes in culture [21]. This biochemical 
specificity coupled with the topical delivery of lower concentra-
tions of MGBG with DFMO may provide a selective and more 
effective therapy for psoriasis and other cutaneous disorders 
associated with abnormalities in polyamine metabolism. 
The authors wish to thank Dr. Peter McCann and Keith Diekema 
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